Active	Status	Sponsor type	Region	Phase	Filter
9 Active 6 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Martin, Stephan
NCT06256497: A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes	Enrolling by invitation	N/A	100	Europe	Duodenal Mucosal Resurfacing (DMR), Revita DMR	Fractyl Health Inc.	Diabetes Mellitus, Type 2	07/28	12/28
NCT04474808: Foot Cream for the Care of Dry and Cracked Skin	Completed	N/A	100	Europe	L-Arginin containing foot cream, Urea-containing foot cream	West German Center of Diabetes and Health, Bionatural GmbH	Diabetes Mellitus	06/23	06/23
NASH, NCT04707651: Formula Diet Treatment for Patients.	Active, not recruiting	N/A	20	Europe	Formula diet	West German Center of Diabetes and Health	Steatohepatitis, Nonalcoholic	12/24	03/25
AimdR, NCT05704491: AI Screening for Diabetic Retinopathy	Recruiting	N/A	100	Europe	artificial intelligence (AI) algorithm of the MONA DR model	West German Center of Diabetes and Health	Diabetes Mellitus	12/24	12/25
WeR-LIM-SMBA, NCT06745362: Weight Reduction with the Low-Insulin-Method - Self Monitoring of Breath Acetone	Not yet recruiting	N/A	42	Europe	self-monitoring of breath acetone, lifestyle-intervention via LIM-App	West German Center of Diabetes and Health	Overweight and Obese Volunteers	12/26	12/26
SEUFERT, Jochen
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
NCT06256497: A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes	Enrolling by invitation	N/A	100	Europe	Duodenal Mucosal Resurfacing (DMR), Revita DMR	Fractyl Health Inc.	Diabetes Mellitus, Type 2	07/28	12/28
COYOTE, NCT06579404: Closed-loop in Adults with Type 2 Diabetes	Recruiting	N/A	224	Europe, RoW	CamAPS HX, Standard insulin therapy with glucose sensor	University of Cambridge, University of Edinburgh, Jaeb Center for Health Research, Swansea University	Type 2 Diabetes Treated with Insulin	03/27	07/27